Double IOP system effective in patients with macular degeneration

Article

The implantation of the double intraocular lens (IOL) system (IOL-VIP) can improve best corrected visual acuity (BCVA) in patients with low vision due to advanced maculopathy, according to a report published in the September issue of the Journal of Cataract and Refractive Surgery.

The implantation of the double intraocular lens (IOL) system (IOL-VIP) can improve best corrected visual acuity (BCVA) in patients with low vision due to advanced maculopathy, according to a report published in the September issue of the Journal of Cataract and Refractive Surgery.

Luis Amselem from the Hospital General Universitario, Valencia, Spain and colleagues evaluated the efficacy of a standard double IOP system in patients with low vision and central scotoma due to macular degeneration. The interventional, prospective, non-comparative case series included 13 consecutive surgical procedures in 10 patients.

At 12-months follow-up the difference between pre- and postoperative BCVA, refraction, position of IOLs, endothelial cell density and occurrences of postoperative complications were evaluated.

At 12-months, mean BCVA was 0.68 logMAR compared with 1.37 logMAR preoperatively. Mean best corrected clinical gain was 44%.

No statistically significant difference between the clinically evaluated and theoretically calculated residual refractions was recorded and there were no intraoperative or postoperative complications.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.